BSE:506197

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. More Details


Snowflake Analysis

Flawless balance sheet with questionable track record.


Similar Companies

Share Price & News

How has Bliss GVS Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 506197's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.2%

506197

4.7%

IN Pharmaceuticals

1.8%

IN Market


1 Year Return

42.4%

506197

51.0%

IN Pharmaceuticals

9.5%

IN Market

Return vs Industry: 506197 underperformed the Indian Pharmaceuticals industry which returned 48.7% over the past year.

Return vs Market: 506197 exceeded the Indian Market which returned 8.8% over the past year.


Shareholder returns

506197IndustryMarket
7 Day1.2%4.7%1.8%
30 Day15.4%2.5%2.2%
90 Day53.2%18.6%13.9%
1 Year42.8%42.4%52.9%51.0%11.6%9.5%
3 Year-4.3%-6.0%28.6%25.0%2.2%-2.7%
5 Year-15.9%-17.9%5.2%1.3%46.0%35.1%

Price Volatility Vs. Market

How volatile is Bliss GVS Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bliss GVS Pharma undervalued compared to its fair value and its price relative to the market?

19.76x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 506197 (₹152.55) is trading above our estimate of fair value (₹6.59)

Significantly Below Fair Value: 506197 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 506197 is good value based on its PE Ratio (19.8x) compared to the IN Pharmaceuticals industry average (22.5x).

PE vs Market: 506197 is poor value based on its PE Ratio (19.8x) compared to the Indian market (16.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 506197's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 506197's PB Ratio (2.1x) is in line with the IN Pharmaceuticals industry average.


Next Steps

Future Growth

How is Bliss GVS Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bliss GVS Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bliss GVS Pharma performed over the past 5 years?

7.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 506197 has high quality earnings.

Growing Profit Margin: 506197's current net profit margins (13.1%) are lower than last year (13.2%).


Past Earnings Growth Analysis

Earnings Trend: 506197's earnings have grown by 7.8% per year over the past 5 years.

Accelerating Growth: 506197's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 506197 had negative earnings growth (-33.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.6%).


Return on Equity

High ROE: 506197's Return on Equity (10.5%) is considered low.


Next Steps

Financial Health

How is Bliss GVS Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 506197's short term assets (₹7.7B) exceed its short term liabilities (₹2.3B).

Long Term Liabilities: 506197's short term assets (₹7.7B) exceed its long term liabilities (₹464.7M).


Debt to Equity History and Analysis

Debt Level: 506197's debt to equity ratio (13.8%) is considered satisfactory.

Reducing Debt: 506197's debt to equity ratio has reduced from 40.6% to 13.8% over the past 5 years.

Debt Coverage: 506197's debt is well covered by operating cash flow (43.7%).

Interest Coverage: 506197's interest payments on its debt are well covered by EBIT (12.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Bliss GVS Pharma current dividend yield, its reliability and sustainability?

0.33%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 506197's dividend (0.33%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.55%).

High Dividend: 506197's dividend (0.33%) is low compared to the top 25% of dividend payers in the Indian market (2.25%).


Stability and Growth of Payments

Stable Dividend: 506197's dividend payments have been volatile in the past 10 years.

Growing Dividend: 506197's dividend payments have not increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (6.5%), 506197's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Shibroor Kamath (67 yo)

14.33yrs

Tenure

₹23,300,000

Compensation

Mr. Shibroor Narasimha Kamath has been the Managing Director of Bliss Gvs Pharma Limited (formerly, Bliss Chemicals & Pharmaceuticals India Ltd) since May 9, 2006 and serves as its Chief executive Officer ...


CEO Compensation Analysis

Compensation vs Market: Shibroor's total compensation ($USD317.15K) is about average for companies of similar size in the Indian market ($USD297.04K).

Compensation vs Earnings: Shibroor's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Shibroor Kamath
CEO, MD & Executive Director14.33yrs₹23.30m33.31%
₹ 5.2b
Vipul Thakkar
Chief Financial Officer5.08yrs₹3.62m0.049%
₹ 7.7m
Aditi Bhatt
Compliance Officer & Company Secretary2.08yrs₹745.00kno data
Vibha Sharma
Executive & Whole Time Director12.17yrs₹4.77mno data
Shruti Vishal Rao
Executive & Whole Time Director14.17yrs₹4.77mno data

5.1yrs

Average Tenure

39.5yo

Average Age

Experienced Management: 506197's management team is seasoned and experienced (5.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Shibroor Kamath
CEO, MD & Executive Director14.33yrs₹23.30m33.31%
₹ 5.2b
Vibha Sharma
Executive & Whole Time Director12.17yrs₹4.77mno data
Shruti Vishal Rao
Executive & Whole Time Director14.17yrs₹4.77mno data
Subramanian Vaidya
Chairman of the Board0.25yr₹120.00kno data
Shilpa Bhatia
Additional Independent Women Director0.58yrno datano data
Santosh Parab
Independent Director4.33yrs₹120.00k0.0022%
₹ 350.9k

4.3yrs

Average Tenure

48yo

Average Age

Experienced Board: 506197's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bliss GVS Pharma Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bliss GVS Pharma Limited
  • Ticker: 506197
  • Exchange: BSE
  • Founded: 1984
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹15.735b
  • Shares outstanding: 103.15m
  • Website: https://www.blissgvs.com

Location

  • Bliss GVS Pharma Limited
  • 102, Hyde Park
  • Saki Vihar Road
  • Mumbai
  • Maharashtra
  • 400072
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
506197BSE (Mumbai Stock Exchange)YesEquity SharesININRJan 2002
BLISSGVSNSEI (National Stock Exchange of India)YesEquity SharesININRJan 2002

Biography

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/17 19:55
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.